Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | AR | P10275 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681219 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AARMAPT | |
| SCHEMBL8123488 | 0.82 | HTR2C (0.47) | USP2ALDH1A1HSD17B10PDK1 | |
| SCHEMBL809829 | 0.76 | RAB9A (1.00) | SMN1; SMN2NPC1RAB9AARMAPT | |
| SCHEMBL21588424 | 0.76 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9AARMAPT | |
| SCHEMBL16896509 | 0.76 | HRH3 (0.60) | SMN1; SMN2NPC1RAB9AARMAPT | |
| SCHEMBL29505245 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AARMAPT | |
| SCHEMBL16896582 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AARMAPT | |
| SCHEMBL21114754 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AARMAPT | |
| SCHEMBL29505280 | 0.76 | HRH3 (0.60) | SMN1; SMN2NPC1RAB9AARMAPT | |
| Hydrogen Sulfide SCHEMBL11606123 | 0.75 | RAB9A (0.97) | SMN1; SMN2NPC1RAB9AARMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | AC IMMUNE SA (CH) | 2023-06-27 | — | — | US | disclosed |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2022-04-28 | — | — | US | disclosed |
| EP-3735411-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC Immune SA (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| WO-2019134978-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC IMMUNE SA (CH) | 2019-07-11 | — | — | WO | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | SMN1; SMN2 445/4885NPC1 290/4885RAB9A 1905/4885 |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | SMN1; SMN2 445/4885NPC1 290/4885RAB9A 1905/4885 |
| US-20220127263-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | SMN1; SMN2 445/4885NPC1 290/4885RAB9A 1905/4885 |
| US-11684625-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates | MAPT, PSEN2, PSEN1 | SMN1; SMN2 343/4885NPC1 144/4885RAB9A 2191/4885 |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | SMN1; SMN2 479/4885NPC1 325/4885RAB9A 2189/4885 |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | SMN1; SMN2 445/4885NPC1 290/4885RAB9A 1905/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | SMN1; SMN2 479/4885NPC1 325/4885RAB9A 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.